Breaking News

Financial Report: AMRI

August 5, 2014

Cedarburg business boosts large scale manufacturing revenue

AMRI

2Q Revenues: $68.2 million (+15%)

2Q Earnings: $3.7 million (loss of $2.5 million in 2Q13)

YTD Revenues: $127.5 million (+7%)

YTD Earnings: $7.2 million (+90%)

Comments: Contract revenue was $61.5 million, up 21% driven by increased capacity utilization and the addition of Cedarburg Pharmaceuticals. Discovery Services and Development/Small Scale Manufacturing (DDS) contract revenue in the quarter was flat at $19.5 million. Large Scale Manufacturing (LSM) contract revenue was $42.0 million, up 34%, which includes $5.5 million of revenues from the Cedarburg business. Royalty revenue in the quarter was $6.7 million, down 21%. Royalties include Allegra products, which continue to face generic competition, as well as $2.5 million from the net sales of certain amphetamine salts sold by Actavis. The company recently acquired Oso Biopharmaceuticals Manufacturing in July 2014, expanding its contract manufacturing capabilities to include commercial scale, complex injectable drug product.

blog comments powered by Disqus
  • Elemental Impurity Testing

    Elemental Impurity Testing

    Dr. Andrew Fussell, PANalytical ||January 28, 2016
    Advances in elemental impurity testing aid compliance with new USP requirements

  • Fit-For-Purpose Assay Development in Bioanalysis

    Fit-For-Purpose Assay Development in Bioanalysis

    Franklin Spriggs, Ligand Binding Assay Group Leader; Ashley Brant, Program Manager, AIT Bioscience||January 28, 2016
    The success of bioanalytical studies relies on the selection of the most suitable analytical method but the timeline of method development and types of analyses involved vary greatly.

  • Optimizing Collaboration Effectiveness in Alliance Partnerships

    Optimizing Collaboration Effectiveness in Alliance Partnerships

    Mary Jo Lamberti, Phil Birch, Ranjana Chakravarthy, Ken Getz, Tufts CSDD||January 28, 2016